Who is recommended to receive COVID-19 vaccines?

ACIP recommended on September 18, 2025 that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness.

Product options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status.

Although the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired.